Blog

Mo's for Bro's Update

Together we are improving prostate cancer diagnostic and treatment options

We have an update on our moustaches for Movember (It’s Movember time to grow a mo for a bro!) and we coordinated our plaid (for Dad) at the same time! Hopefully, your Movember was as successful. APCaRI wants to send a thank you to Movember and Prostate Cancer Canada for their Men’s Health Awareness Drives. How else can we get our moustaches AND plaid on at the same time!
In the spirit of gratitude, APCaRI also recognizes our research staff for their hard work and dedication to improving prostate cancer care and future outcomes AND the nurses, oncologists, and urologists who work every day to help the men and their families touched by prostate cancer. Please know that your devotion to the patients and their treatment needs is greatly appreciated.

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Recent Posts

15th Annual Personalized Medicine Conference Posted on Nov 9 19 at 5:14pm
Evaluating the measurement properties of EPIC-26 Posted on Nov 6 19 at 12:19pm
APCaRI 2019 Fall Symposium Posted on Oct 22 19 at 12:28pm

New platform for prostate cancer diagnosis to be presented at ISEV 2017

The Lewis Research Group will present exciting results about new blood tests for prostate cancer during 3 talks at the upcoming 2017 International Society of Extracellular Vesicles (ISEV) annual meeting in Toronto (May 18-21). ISEV is a global society of researchers studying exosomes and microvesicles, which are the exciting new focus of cancer therapy and diagnosis.

Dr. Desmond Pink will speak about “Microflow cytometry: The Apogee A50 is a sensitive standard tool for extracellular vesicle analyses in liquid biopsies”, Robert Paproski’s presentation is entitled “Using machine learning of extracellular vesicle flow cytometry to build predictive fingerprints for prostate cancer diagnosis”, and Dr. John Lewis will speak about “An extracellular vesicle blood fingerprint distinguishes between patients with indolent and aggressive prostate cancer at diagnosis”.

The team is looking forward to sharing these key advances that were made possible through the APCaRI prospective cohort.

- John Lewis